* LifeMD Inc LFMD.OQ LFMD.O is expected to show a rise
in
quarterly revenue when it reports results on May 8 for the
period ending March 31 2024
* The New York City-based company is expected to report a
28.4% increase in revenue to $42.54 million from $33.13 million
a year ago, according to the mean estimate from 5 analysts,
based on LSEG data.The company's guidance on March 11 2024, for
the period ended March 31, was for revenue between $42.00
million and $43.00 million.
* LSEG's mean analyst estimate for LifeMD Inc is for a loss
of 15
cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for LifeMD Inc
is
$12.00, below its last closing price of $12.44.
The company's guidance on March 11 2024 for the period ended
March 31 was for Earnings before Interest, Taxes, Depreciation
and Amortization of between USD42 million and USD2 million.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Dec. 31 2023 -0.12 -0.14 -0.12 Beat 14.3
Sep. 30 2023 -0.15 -0.15 -0.20 Missed -29
Jun. 30 2023 -0.10 -0.10 -0.23 Missed -122.6
Mar. 31 2023 -0.16 -0.16 -0.15 Beat 6.3
Dec. -0.18 -0.18 -0.40 Missed -122.2
31 2022
Sep. 30 2022 -0.30 -0.28 -0.26 Beat 8.8
Jun. 30 2022 -0.35 -0.35 -0.45 Missed -28.6
Mar. 31 2022 -0.41 -0.36 -0.46 Missed -26
This summary was machine generated May 6 at 23:23 GMT. All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)